West Pharmaceutical Services
WST · What the business does, what can go wrong, and how options sellers approach it
What it does
West Pharmaceutical Services makes the packaging and delivery components that sit around injectable medicines. Its products include rubber-like stoppers, seals and plungers for vials and syringes, plus containment systems and devices such as auto-injectors. Drugmakers, including makers of biologics, generics and peptide therapies, use these parts to store and deliver their products.
How it makes money
West reports in two segments. Proprietary products are West-designed components and systems sold to drug companies, usually the higher-margin side. Contract-manufactured products are devices and assemblies built to a customer's specifications.
Many of its components are specified into a drug's regulatory filing. Once a medicine is approved with a particular part, switching suppliers can be slow and costly, which tends to make revenue recurring for as long as the drug sells.
Why investors own it
- Exposure to injectable drugs, a category tied to biologics and other complex therapies, without depending on any single drug succeeding.
- Switching costs created by regulatory qualification and quality requirements.
- A mix of consumable-style components and higher-value delivery systems.
- Sales across many regions and customers.
What can go wrong
- Customers sometimes draw down or build inventory, which can make orders lumpy.
- Demand for specific product lines, such as those tied to a popular drug class, can swing.
- Manufacturing or quality problems can be costly in a regulated industry.
- Raw material, energy and labor costs can pressure margins.
- Large capacity investments may take time to pay off, or may not.
- Currency moves affect reported results because of its international sales.
What to watch
- Organic sales growth by segment
- Operating margin trends
- Customer order and destocking commentary
- Mix of high-value components versus standard ones
- Capital spending and new capacity coming online
- Guidance changes at quarterly earnings
- Regulatory or quality-related disclosures
Options income angle
Options on WST are generally available across several expirations, though liquidity is usually thinner than for the largest mega-cap names. Wider bid-ask spreads can raise trading costs, especially for strikes far from the current price.
Implied volatility tends to rise ahead of quarterly earnings and when guidance or customer inventory trends are in question. It often falls after the report.
One caution for premium sellers: this stock has historically been capable of large single-day moves after earnings, and a covered call or cash-secured put can leave you exposed to a sharp gap that the premium collected may not offset.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 17, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
West Pharmaceutical Services makes packaging and delivery systems for injectable drugs. In 2025 it reported consolidated net sales of $3,074.1 million, up 6.3%, and GAAP operating profit of $584.9 million. The filing links much of its business to injectable drugs such as GLP-1s, sold to a limited number of customers, and flags that a shift away from injection would hurt it.
How the business did
- Sales: Consolidated net sales rose 6.3%, or 4.3% excluding currency effects. Proprietary Products grew 6.8% to $2,492.1 million on demand for Westar®, NovaChoice® and Envision® products, despite approximately $47 million in customer incentives received for 2024 volumes that were not repeated. Contract-Manufactured Products grew 4.2% to $582.0 million, helped by self-injection devices for obesity and diabetes.
- Profit: Diluted EPS was $6.79, against $6.69 a year earlier. Adjusted EPS, which strips out items management calls unrepresentative of ongoing operations, was $7.29. Consolidated gross profit margin was 35.9%, against 34.5%. Contract-Manufactured operating profit fell 12.3% on higher production costs, and SG&A (selling, general and administrative) costs rose 16.3% on higher incentive compensation and salaries.
- Cash and capital return: Operating cash flow was $754.8 million, against $653.4 million. Financing outflows fell to $185.1 million from $622.6 million, mainly because of fewer share repurchases. Year-end cash was $791.3 million and debt was $202.8 million.
- Unusual items: Restructuring and other charges were $23.3 million. The agreed sale of the SmartDose® 3.5mL On-Body Delivery System to AbbVie brought $8.4 million of charges, and a cost-method investment impairment was $4.5 million. Management said tariffs were not material to 2025 results.
Risks specific to this company
- Injection dependence: Sales and profit depend heavily on injected drugs such as GLP-1s. Oral alternatives, less frequent dosing or needle-free technology could reduce demand.
- Customer concentration: A substantial portion of revenue comes from a limited number of customers. Losing one or a big drop in its orders could materially hurt results.
- Single-source supply and input costs: Many components and raw materials come from a single supplier, and FDA rules make replacements slow to qualify. Elastomers, aluminum and plastic are the three basic raw materials, and price increases have historically taken time to pass on to customers.
- Daikyo licenses: Crystal Zenith, FluroTec® and B2-coating technologies are licensed from affiliate Daikyo under agreements that expire in 2027. Early termination or non-renewal could cost the company access to them.
- International exposure: Sales outside the U.S. were 56.7% of consolidated net sales in 2025. Currency swings, tariffs and political conditions affect results, and hedges may not be effective.
- Concentrated plants: For some product lines, manufacturing sits in only one or a few plants, so a disruption at one site could limit the company's ability to make and sell those products.
What management is watching
- New products: R&D costs were $74.3 million, up 7.5%, with investment in the Synchrony™ Prefillable Syringe (PFS) System, which launched in January 2026, and in engineered plastics and components.
- SmartDose sale: The agreement to sell SmartDose® 3.5mL to AbbVie moved held-for-sale assets into other current assets. The filing describes the execution of such divestitures as a risk.
- Capacity and demand: Management is working to increase capacity through its capital strategy. Inventories grew, mainly work-in-progress and finished goods, to support customer demand.
- Liquidity: Borrowing capacity under the multi-currency revolving credit facility was $497.7 million, with no outstanding borrowings. Management expects to stay in compliance with its debt covenants throughout 2026.
- Non-GAAP measures: Management points to organic net sales and adjusted operating profit, which was $622.4 million at a margin of 20.2%. These exclude currency effects, acquisitions and divestitures, and unallocated items. They are not a substitute for GAAP figures.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 29, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
West Pharmaceutical Services reported third-quarter net sales of $874.5 million, up 8.7%, led by strong demand for its high-value injectable components used in biologics and GLP-1 drugs. Reported profit was lifted by a $55.7 million gain on selling its SmartDose® 3.5mL On-Body Delivery System to AbbVie, so the adjusted figures give a cleaner read. The May 2026 cyberattack also weighed on the West Vantage segment.
How the business did
- Sales: Excluding currency and the SmartDose® 3.5mL sale, organic net sales rose 11.9% in the quarter. Volume and mix added $58.3 million and price increases added $33.6 million. For the nine months, net sales were $2,591.7 million, up 14.2%.
- Profit: Operating profit was $267.4 million versus $167.6 million a year earlier. Adjusted operating profit, which strips out items management calls unrepresentative of ongoing operations, was $221.5 million versus $170.1 million. Diluted earnings per share were $3.02 as reported and $2.66 adjusted, compared with $1.96 adjusted a year earlier.
- Segments: Proprietary Products gross margin rose to 44.4% from 40.8%, helped by a favorable mix of HVP (high-value product) components, including GLP-1 products. West Vantage net sales fell 7.3% after a planned continuous glucose monitoring contract expired, and its gross margin fell to 16.5% from 19.3%. Nine-month West Vantage results also reflect production downtime from the May 2026 cyber incident.
- Cash and capital return: Nine-month operating cash flow was $403.4 million versus $503.7 million, as receivables and inventory grew. The company bought back 2,424,121 shares for $685.3 million. Cash fell to $464.1 million from $791.3 million at December 31, 2025, and debt was $202.9 million.
What management is watching
- Management does not expect tariffs, including the IEEPA tariff refunds it began receiving in the second quarter, to have a material impact on 2026 results. It said the same about the Middle East conflict and related energy and raw-material costs.
- R&D spending was $18.3 million for the quarter, directed at elastomeric components, drug containment, self-injection systems and drug administration consumables.
- The company completed a refinancing of its senior unsecured credit facilities on October 26, 2026. It reported no borrowings under its revolving credit facility, with $497.7 million of capacity available.
- Management points investors to organic net sales (which exclude currency, acquisitions and divestitures) and adjusted operating profit margin, which was 25.3% for the quarter.
New or changed risks
- The cybersecurity risk factor was the only one changed. It now describes a material attack in May 2026 in which data was exfiltrated and systems were encrypted. The company says the incident is contained and operations have fully recovered.
- The filing says attack techniques keep evolving, including through the use of artificial intelligence, and that the company cannot anticipate all of them.
- The filing warns that the costs of mitigating data security risks could be significant and are likely to increase. It also says insurance limits may not cover all losses, damages or fines.
Follow WST in Kortex
The Kortex app shows WST's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.